These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 26183790)

  • 1. Independent Assessment of the European Society of Cardiology Sudden Death Risk Model for Hypertrophic Cardiomyopathy.
    Maron BJ; Casey SA; Chan RH; Garberich RF; Rowin EJ; Maron MS
    Am J Cardiol; 2015 Sep; 116(5):757-64. PubMed ID: 26183790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy.
    O'Mahony C; Tome-Esteban M; Lambiase PD; Pantazis A; Dickie S; McKenna WJ; Elliott PM
    Heart; 2013 Apr; 99(8):534-41. PubMed ID: 23339826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of the 2014 European Society of Cardiology guidelines risk prediction model for the primary prevention of sudden cardiac death in hypertrophic cardiomyopathy.
    Vriesendorp PA; Schinkel AF; Liebregts M; Theuns DA; van Cleemput J; Ten Cate FJ; Willems R; Michels M
    Circ Arrhythm Electrophysiol; 2015 Aug; 8(4):829-35. PubMed ID: 25922410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
    Maron BJ; Spirito P; Shen WK; Haas TS; Formisano F; Link MS; Epstein AE; Almquist AK; Daubert JP; Lawrenz T; Boriani G; Estes NA; Favale S; Piccininno M; Winters SL; Santini M; Betocchi S; Arribas F; Sherrid MV; Buja G; Semsarian C; Bruzzi P
    JAMA; 2007 Jul; 298(4):405-12. PubMed ID: 17652294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy.
    Maron BJ; Spirito P; Ackerman MJ; Casey SA; Semsarian C; Estes NA; Shannon KM; Ashley EA; Day SM; Pacileo G; Formisano F; Devoto E; Anastasakis A; Bos JM; Woo A; Autore C; Pass RH; Boriani G; Garberich RF; Almquist AK; Russell MW; Boni L; Berger S; Maron MS; Link MS
    J Am Coll Cardiol; 2013 Apr; 61(14):1527-35. PubMed ID: 23500286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of the 2014 European Society of Cardiology Sudden Cardiac Death Risk Prediction Model Among Various Phenotypes in Japanese Patients With Hypertrophic Cardiomyopathy.
    Nakagawa S; Okada A; Nishimura K; Hamatani Y; Amano M; Takahama H; Amaki M; Hasegawa T; Kanzaki H; Kusano K; Yasuda S; Izumi C
    Am J Cardiol; 2018 Dec; 122(11):1939-1946. PubMed ID: 30293654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting therapies in Japanese hypertrophic cardiomyopathy patients with an implantable cardioverter-defibrillator using the 2014 European Society of Cardiology guidelines.
    Nakano M; Kondo Y; Nakano M; Kajiyama T; Miyazawa K; Hayashi T; Ito R; Takahira H; Kobayashi Y
    Heart Vessels; 2021 Jan; 36(1):99-104. PubMed ID: 32666207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary prevention implantable cardioverter-defibrillators in hypertrophic cardiomyopathy-Are there predictors of appropriate therapy?
    Weissler-Snir A; Dorian P; Rakowski H; Care M; Spears D
    Heart Rhythm; 2021 Jan; 18(1):63-70. PubMed ID: 32800967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of newer cardiac magnetic resonance-based risk markers for sudden death prevention in hypertrophic cardiomyopathy: An international multicenter study.
    Rowin EJ; Maron MS; Adler A; Albano AJ; Varnava AM; Spears D; Marsy D; Heitner SB; Cohen E; Leong KMW; Winters SL; Martinez MW; Koethe BC; Rakowski H; Maron BJ
    Heart Rhythm; 2022 May; 19(5):782-789. PubMed ID: 34933112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up.
    Syska P; Przybylski A; Chojnowska L; Lewandowski M; Sterliński M; Maciag A; Gepner K; Pytkowski M; Kowalik I; Maczyńska-Mazuruk R; Ruzyłło W; Szwed H
    J Cardiovasc Electrophysiol; 2010 Aug; 21(8):883-9. PubMed ID: 20132378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A validation study of the European Society of Cardiology guidelines for risk stratification of sudden cardiac death in childhood hypertrophic cardiomyopathy.
    Norrish G; Ding T; Field E; McLeod K; Ilina M; Stuart G; Bhole V; Uzun O; Brown E; Daubeney PEF; Lota A; Linter K; Mathur S; Bharucha T; Kok KL; Adwani S; Jones CB; Reinhardt Z; Omar RZ; Kaski JP
    Europace; 2019 Oct; 21(10):1559-1565. PubMed ID: 31155643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of risk stratification and sudden death prevention in hypertrophic cardiomyopathy: Twenty years with the implantable cardioverter-defibrillator.
    Maron BJ; Rowin EJ; Maron MS
    Heart Rhythm; 2021 Jun; 18(6):1012-1023. PubMed ID: 33508516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of family history of sudden death in risk stratification and prevention of sudden death with implantable defibrillators in hypertrophic cardiomyopathy.
    Bos JM; Maron BJ; Ackerman MJ; Haas TS; Sorajja P; Nishimura RA; Gersh BJ; Ommen SR
    Am J Cardiol; 2010 Nov; 106(10):1481-6. PubMed ID: 21059440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the Prognostic Usefulness of the European Society of Cardiology and American Heart Association/American College of Cardiology Foundation Risk Stratification Systems for Patients With Hypertrophic Cardiomyopathy.
    Leong KMW; Chow JJ; Ng FS; Falaschetti E; Qureshi N; Koa-Wing M; Linton NWF; Whinnett ZI; Lefroy DC; Davies DW; Lim PB; Peters NS; Kanagaratnam P; Varnava AM
    Am J Cardiol; 2018 Feb; 121(3):349-355. PubMed ID: 29203036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [14-year experience with implantable cardioverter/defibrillators: determination of prognosis and discharge behavior].
    Vester EG; Dees H; Dobran I; Hennersdorf M; Perings C; Heydthausen M; Winter J; Strauer BE
    Z Kardiol; 2000; 89 Suppl 3():194-205. PubMed ID: 10810803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Programmed ventricular stimulation predicts arrhythmic events and survival in hypertrophic cardiomyopathy.
    Gatzoulis KA; Georgopoulos S; Antoniou CK; Anastasakis A; Dilaveris P; Arsenos P; Sideris S; Tsiachris D; Archontakis S; Sotiropoulos E; Theopistou A; Skiadas I; Kallikazaros I; Stefanadis C; Tousoulis D
    Int J Cardiol; 2018 Mar; 254():175-181. PubMed ID: 29407088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement in sudden cardiac death risk prediction by the enhanced American College of Cardiology/American Heart Association strategy in Chinese patients with hypertrophic cardiomyopathy.
    Liu J; Wu G; Zhang C; Ruan J; Wang D; Zhang M; Wang L; Yang Y; Li X; Wang Y; Hui R; Zou Y; Kang L; Wang J; Song L
    Heart Rhythm; 2020 Oct; 17(10):1658-1663. PubMed ID: 32311532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy.
    Maron BJ; Shen WK; Link MS; Epstein AE; Almquist AK; Daubert JP; Bardy GH; Favale S; Rea RF; Boriani G; Estes NA; Spirito P
    N Engl J Med; 2000 Feb; 342(6):365-73. PubMed ID: 10666426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypertrophic Cardiomyopathy in Adulthood Associated With Low Cardiovascular Mortality With Contemporary Management Strategies.
    Maron BJ; Rowin EJ; Casey SA; Link MS; Lesser JR; Chan RH; Garberich RF; Udelson JE; Maron MS
    J Am Coll Cardiol; 2015 May; 65(18):1915-28. PubMed ID: 25953744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contemporary strategies for risk stratification and prevention of sudden death with the implantable defibrillator in hypertrophic cardiomyopathy.
    Maron BJ; Maron MS
    Heart Rhythm; 2016 May; 13(5):1155-1165. PubMed ID: 26749314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.